{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:48:06Z","timestamp":1794361686003,"version":"4.9.0"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1001\/jamacardio.2018.2258","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T16:37:36Z","timestamp":1533141456000},"page":"823","source":"Crossref","is-referenced-by-count":198,"title":["Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels"],"prefix":"10.1001","volume":"3","author":[{"given":"Marc S.","family":"Sabatine","sequence":"first","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Deputy Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Wiviott","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KyungAh","family":"Im","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10059","key":"hoi180035r1","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy.","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"hoi180035r2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"9753","key":"hoi180035r3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"hoi180035r4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement.","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"25","key":"hoi180035r5","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"hoi180035r6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi180035r7","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/jamacardio.2017.3944","article-title":"Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial.","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"13","key":"hoi180035r8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease.","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"hoi180035r9","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial.","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"10106","key":"hoi180035r10","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"14","key":"hoi180035r11","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","article-title":"2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"hoi180035r12","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","article-title":"2017 Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.","volume":"39","author":"Landmesser","year":"2018","journal-title":"Eur Heart J"},{"issue":"4","key":"hoi180035r13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jacl.2017.05.001","article-title":"Update on the use of PCSK9 inhibitors in adults: recommendations from an expert panel of the National Lipid Association.","volume":"11","author":"Orringer","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"8","key":"hoi180035r14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jama.2017.9924","article-title":"Updated Cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial.","volume":"318","author":"Kazi","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"hoi180035r15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","article-title":"Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease.","volume":"2","author":"Fonarow","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"9","key":"hoi180035r16","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamacardio.2017.2293","article-title":"Low-density lipoprotein cholesterol treatment in the proprotein convertase subtilisin\/kexin type 9 inhibitor era: getting back on target.","volume":"2","author":"Sabatine","year":"2017","journal-title":"JAMA Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2695047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T12:08:50Z","timestamp":1537358930000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2018.2258"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2018.2258","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733724186.793551823","asserted-by":"object"}]},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}